PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL.

ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle  Grobelny JV, Godwin AK, Broccoli D.

The puzzling multiple lives of PML and its role in the genesis of cancer  Ruggero D, Wang ZG, Pandolfi PP.

A PML/RARA chimeric gene on chromosome 2 in a patient with acute promyelocytic leukemia  Fujishima M, Takahashi N, Miura I, Kobayashi Y, Kume M, Nishinari T, Miura AB.

Two new 3' PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia Chillon MC, Gonzalez M, Garcia-Sanz R, Balanzategui A, Gonzalez D, Lopez-Perez R, Mateos MV, Alaejos I, Rayon C, Arbeteta J, Hernandez JM, Orfao A, San Miguel J.

PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells  Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB.

Occurrence of a novel t(11;19)(q13;q13.3) in complete remission of acute promyelocytic leukemia Temperani P, Luppi M, Giacobbi F, Vaccari P, Longo G, Donelli A, Narni F, Torelli G, Emilia G.

Chromosomal abnormalities and oncogenes  Mitani K.

Breakpoint clusters of the PML gene in acute promyelocytic leukemia  Dong S, Geng JP, Tong JH, Wu Y, Cai JR, Sun GL, Chen SR, Wang ZY, Larsen CJ, Berger R, et al.

Localization of the chromosome 15 breakpoints and expression of multiple PML-RAR alpha transcripts in acute promyelocytic leukemia(in chinese)  Geng JP, Tong JH, Dong S, Wang ZY, Chen SJ, Chen Z, Zelent A, Berger R, Larsen CJ.

Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice  He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP.

Diagnostic approaches to acute promyelocytic leukaemia  O'Connor SJ, Evans PA, Morgan GJ.

Acute promyelocytic leukemia: a curable disease  Lo Coco F, Nervi C, Avvisati G, Mandelli F.

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase   Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP.

ATRA(ouble) in the treatment of acute promyelocytic leukemia  Ozpolat B, Lopez-Berestein G, Mehta K.

Fibroblast growth factor-8b-stimulated myogenic cell proliferation is suppressed by the promyelocytic leukemia gene  Kwong WH, Tang MK, Yew DT, Chan JY, Cai DQ, Tong WM, Lee KK.

Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity   Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y.

Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller WH Jr.

Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines  Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH Jr.

Visualization of gene activity in living cells  Tsukamoto T, Hashiguchi N, Janicki SM, Tumbar T, Belmont AS, Spector DL

Development of APL is the formation of a PML/RARA chimeric gene, regardless of its locus in the genome  Fujishima M, Takahashi N, Miura I, Kobayashi Y, Kume M, Nishinari T, Miura AB.

Acute promyelocytic leukemia with del(6)(p23)  Nakase K, Wakita Y, Minamikawa K, Yamaguchi T, Shiku H.

Two new 3' PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia  Chillon MC, Gonzalez M, Garcia-Sanz R, Balanzategui A, Gonzalez D, Lopez-Perez R, Mateos MV, Alaejos I, Rayon C, Arbeteta J, Hernandez JM, Orfao A, San Miguel J.

PML/RARalpha, a fusion protein in acute promyelocytic leukemia  Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB.

Breakpoint clusters of the PML gene in acute promyelocytic leukemia   Dong S, Geng JP, Tong JH, Wu Y, Cai JR, Sun GL, Chen SR, Wang ZY, Larsen CJ, Berger R, et al.

Localization of the chromosome 15 breakpoints and expression of multiple PML-RAR alpha transcripts in acute promyelocytic leukemia ( a study of 28 Chinese patients)  Geng JP, Tong JH, Dong S, Wang ZY, Chen SJ, Chen Z, Zelent A, Berger R, Larsen CJ.

ATRA(ouble) in the treatment of acute promyelocytic leukemia  Ozpolat B, Lopez-Berestein G, Mehta K.

The majority of patients with acute promyelocytic leukemia possess either a bcr1 or a bcr3 type fusion between PML and RARalpha genes  Bolognesi E, Cimino G, Diverio D, Rapanotti MC, D'Alfonso S, Fleischhauer K, Migliaretti G, Momigliano-Richiardi P.

Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia  Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller WH Jr.

Alterations in subnuclear trafficking of nuclear regulatory factors in acute leukemia  Meyers S, Hiebert SW.

Oligomerization of a transcription factor, imposing an altered interaction with transcriptional coregulators, represents a novel mechanism of oncogenic activation  Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG.

Biochemical framework for understanding the transformation suppression activity of PML  Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL.

The PML-RARa transcript in long-term follow-up of acute promyelocytic leukemia patients  Gameiro P, Vieira S, Carrara P, Silva AL, Diamond J, de Sousa AB, Mehta AB, Prentice HG, Guimaraes JE, Hoffbrand AV, Foroni L, Parreira A.

Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia   Pandolfi PP.

Role of PML protein in tumor suppression  Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP.

PML and COP1--two proteins with much in common  Reyes JC.

Differences in target gene recognition by the normal and oncogenic RARalpha proteins may contribute to the leukemogenic phenotype  Hauksdottir H, Privalsky ML.

PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype  Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, Luchetti L, Masella B, Morsilli O, Pelosi E, Samoggia P, Pelicci PG, Peschle C.

Lack of expression for the suppressor PML in human small cell lung carcinoma  Zhang P, Chin W, Chow LT, Chan AS, Yim AP, Leung SF, Mok TS, Chang KS, Johnson PJ, Chan JY.

Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance  Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG.

BLM is part of a dynamic nuclear matrix-based complex that requires PML and functions during G2 in undamaged cells and recombinational repair after DNA damage  Bischof O, Kim SH, Irving J, Beresten S, Ellis NA, Campisi J.